Nexalin signs 10-year exclusive distribution deal for Nexalin Sync across seven South American countries

Nexalin Technology, Inc.

10-year exclusive distribution rights for Nexalin Sync across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela (300M+ people), auto-renewing for successive 10-year terms.
Binding initial purchase order at signing; 5 Nexalin Sync devices delivered for a Brazil clinical pilot targeted within 90 days, with 5 more ordered within 12 months.
Initial 100-device commercialization program with tiered per-device pricing; exclusivity requires minimum revenue to Nexalin within 30 months of pilot launch, then annually.
At 30 devices purchased, distributor INOVANEXA MEDICAL TECHNOLOGIES S.A. must build a Brazil plant at its own cost; Nexalin gets fixed per-device fees plus royalties on disposable electrodes.
Nexalin keeps all IP and exclusively supplies encrypted circuit boards; ANVISA approval covers anxiety, depression and insomnia; USP trial reported 77.8% anxiety response.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.